Bioprocessing - Upstream & Downstream

Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.

Edd Stone of TTP explains how the industry is overcoming the manufacturing challenges associated with cell therapies.

What role can regulators play in overcoming the barriers to the adoption of continuous manufacturing processes?

Why is there a need for innovation in cell line development technology?

Nominations are now open for The Medicine Maker 2021 Innovation Awards.

Is there data demonstrating significant cost benefits from continuous biomanufacturing?

How do we choose the right bioprocessing technologies for the short and long term?

We speak with G-CON’s Maik Jornitz about his career and desire to give back by training the next generation.

Watch our video interview with Maik Jornitz.

To speed up vaccine development, we need to assess our bioconjugation approaches.